Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 59% · refreshes every 15s during session
ImmunityBio, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Revenue +94% YoY in Q2 FY2026.
2 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 22d ago
IBRX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on IBRX.
Free accounts see more of this; Premium sees all of it.
Reported figures for ImmunityBio, Inc. — research only, not investment advice.
Updated
What happened recently for ImmunityBio, Inc. (IBRX) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
AlphaOS industries
Investment snapshot
IBRX's AI investment thesis
Upgrade to Premium for IBRX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Latest price
$8.44
Market cap
$8.95B
Profitable
No
Revenue $51.24M
Net income
$-230.38M
FY Sep 25, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for ImmunityBio, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow ImmunityBio, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.